Association Between Cardiometabolic Index and Hepatic Steatosis and Liver Fibrosis: a Population-based Study

Overview

Journal Hormones (Athens)

Specialty Endocrinology

Date 2024 Jun 11

PMID 38861108

Authors

Lulu Cheng

Qinggang Wu

Siyu Wang

Affiliations

Soon will be listed here.

Abstract

Background: The cardiometabolic index (CMI) is a new type of obesity index that is based on a combination of lipid levels and abdominal obesity indicators. It is closely correlated with the occurrence of diabetes mellitus, atherosclerosis, hypertension, and other diseases, thus playing an important role in the screening of metabolic diseases. This is coupled with hepatic steatosis and fibrosis which are characterized by excessive liver fat deposition. The aim of this study was to investigate the possible association between CMI and hepatic steatosis and liver fibrosis.

Methods: A cross-sectional investigation was conducted using the 2017-2020 National Health and Nutrition Examination Survey (NHANES) dataset to probe the relationship between CMI and hepatic steatosis and liver fibrosis, while multiple linear regression models were used to test the linear association between CMI and controlled attenuation parameter (CAP) and liver stiffness measurement (LSM). Smooth-fit curves and threshold effects analysis were used to describe the nonlinear relationships. Subgroup analyses were performed according to gender, age, body mass index (BMI), hypertension, diabetes, cardiovascular disease, and smoking status.

Results: A total of 3084 adults aged 18-80 years were included in this analysis, and after controlling for a variety of variables, there was a significant positive correlation between CMI and CAP [20.38 (16.27,24.49)]. When subgroups were analyzed, this positive correlation was found to be stronger in the female population than in the male (P for interaction = 0.0303). Furthermore, the association between CMI and CAP was nonlinear. Using multiple regression analysis, it was shown that the linear relationship between CMI and liver fibrosis was not significant [-0.09 (-0.47,0.29)].

Conclusions: The findings suggest that elevated CMI levels are associated with hepatic steatosis, but that CMI is not linked to liver fibrosis. Larger prospective investigations are needed to confirm our findings.

Citing Articles

Dietary Nutritional Supplements Are Associated with the Deterioration of Hepatic Fibrosis in Women and Individuals without Underlying Disease.

Cha M, Lee S, Han K Int J Environ Res Public Health. 2024; 21(10).

PMID: 39457270 PMC: 11506959. DOI: 10.3390/ijerph21101298.

References

Fan N, Ding X, Zhen Q, Gu L, Zhang A, Shen T . Association of the Non-Alcoholic Fatty Liver Disease Fibrosis Score with subclinical myocardial remodeling in patients with type 2 diabetes: A cross-sectional study in China. J Diabetes Investig. 2020; 12(6):1035-1041. PMC: 8169360. DOI: 10.1111/jdi.13430. View

Long M, Gandhi S, Loomba R . Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease. Metabolism. 2020; 111S:154259. PMC: 7529729. DOI: 10.1016/j.metabol.2020.154259. View

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

Siddiqui M, Vuppalanchi R, Van Natta M, Hallinan E, Kowdley K, Abdelmalek M . Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2018; 17(1):156-163.e2. PMC: 6203668. DOI: 10.1016/j.cgh.2018.04.043. View

Eddowes P, Sasso M, Allison M, Tsochatzis E, Anstee Q, Sheridan D . Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019; 156(6):1717-1730. DOI: 10.1053/j.gastro.2019.01.042. View

Isabela Andronescu C, Purcarea M, Babes P . The role of noninvasive tests and liver biopsy in the diagnosis of nonalcoholic fatty liver disease. J Med Life. 2018; 11(3):243-246. PMC: 6197518. DOI: 10.25122/jml-2018-1002. View

Liu Y, Wang W . Sex-specific contribution of lipid accumulation product and cardiometabolic index in the identification of nonalcoholic fatty liver disease among Chinese adults. Lipids Health Dis. 2022; 21(1):8. PMC: 8759215. DOI: 10.1186/s12944-021-01617-3. View

Alon L, Corica B, Raparelli V, Cangemi R, Basili S, Proietti M . Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Prev Cardiol. 2021; 29(6):938-946. DOI: 10.1093/eurjpc/zwab212. View

Wakabayashi I, Daimon T . The "cardiometabolic index" as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus. Clin Chim Acta. 2014; 438:274-8. DOI: 10.1016/j.cca.2014.08.042. View

10.

Katsiki N, Perez-Martinez P, Anagnostis P, Mikhailidis D, Karagiannis A . Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?. Curr Vasc Pharmacol. 2017; 16(3):219-227. DOI: 10.2174/1570161115666170621075619. View

11.

Yang N, Lu Y, Cao L, Lu M . The association between non-alcoholic fatty liver disease and serum ferritin levels in American adults. J Clin Lab Anal. 2022; 36(2):e24225. PMC: 8841169. DOI: 10.1002/jcla.24225. View

12.

Ciardullo S, Perseghin G . Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. Metabolism. 2021; 121:154752. DOI: 10.1016/j.metabol.2021.154752. View

13.

Roulot D, Czernichow S, Le Clesiau H, Costes J, Vergnaud A, Beaugrand M . Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol. 2008; 48(4):606-13. DOI: 10.1016/j.jhep.2007.11.020. View

14.

Zou J, Xiong H, Zhang H, Hu C, Lu S, Zou Y . Association between the cardiometabolic index and non-alcoholic fatty liver disease: insights from a general population. BMC Gastroenterol. 2022; 22(1):20. PMC: 8756663. DOI: 10.1186/s12876-022-02099-y. View

15.

Pelusi S, Cespiati A, Rametta R, Pennisi G, Mannisto V, Rosso C . Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. Clin Gastroenterol Hepatol. 2019; 17(11):2310-2319.e6. DOI: 10.1016/j.cgh.2019.01.027. View

16.

Polyzos S, Kountouras J, Mantzoros C . Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2018; 92:82-97. DOI: 10.1016/j.metabol.2018.11.014. View

17.

Wakabayashi I, Sotoda Y, Hirooka S, Orita H . Association between cardiometabolic index and atherosclerotic progression in patients with peripheral arterial disease. Clin Chim Acta. 2015; 446:231-6. DOI: 10.1016/j.cca.2015.04.020. View

18.

Alves-Bezerra M, Cohen D . Triglyceride Metabolism in the Liver. Compr Physiol. 2018; 8(1):1-8. PMC: 6376873. DOI: 10.1002/cphy.c170012. View

19.

Xin Y, Wang Y, Chi J, Zhu X, Zhao H, Zhao S . Elevated free fatty acid level is associated with insulin-resistant state in nondiabetic Chinese people. Diabetes Metab Syndr Obes. 2019; 12:139-147. PMC: 6342222. DOI: 10.2147/DMSO.S186505. View

20.

Tutunchi H, Naeini F, Mobasseri M, Ostadrahimi A . Triglyceride glucose (TyG) index and the progression of liver fibrosis: A cross-sectional study. Clin Nutr ESPEN. 2021; 44:483-487. DOI: 10.1016/j.clnesp.2021.04.025. View